Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00631995
Other study ID # MET32
Secondary ID
Status Completed
Phase Phase 1
First received February 29, 2008
Last updated February 5, 2018
Start date April 2008
Est. completion date April 2009

Study information

Verified date February 2018
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is aimed at studying quadrivalent meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine (TetraMen-T) formulations in Toddlers.

Primary Objectives: Safety and Immunogenicity:

To describe the safety and immunogenicity profiles of:

- A single dose of each formulation of TetraMen-T vaccine

- A single dose of NeisVac-C® vaccine.


Description:

The study is designed to evaluate the safety profile and the immunogenicity response after a single dose of TetraMen-T in toddlers.


Recruitment information / eligibility

Status Completed
Enrollment 360
Est. completion date April 2009
Est. primary completion date February 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Months to 12 Months
Eligibility Inclusion Criteria :

- Subject is healthy, as determined by medical history and physical assessment.

- Aged 12 months (± 21 days) on the day of inclusion.

- Institutional Review Board (IRB)-approved informed consent form signed by the subject's parent/legal guardian.

- Able to attend all scheduled visits and to comply with all trial procedures.

Exclusion Criteria :

- Serious acute or chronic disease (e.g., cardiac, renal, metabolic, rheumatologic, psychiatric, hematologic, or autoimmune disorders, diabetes, atopic conditions, congenital defects, convulsions, encephalopathy, blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic system, acute untreated tuberculosis) that could interfere with trial conduct or completion.

- Known or suspected impairment of immunologic function.

- Acute medical illness within the last 72 hours, or temperature = 37.5ºC (axillary) at the time of enrollment (temporary contraindication).

- History of documented invasive meningococcal disease or previous meningococcal vaccination.

- Known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C seropositivity as reported by the parent or legal guardian.

- Received either immune globulin or other blood products within the last 3 months, or received injected or oral corticosteroids or other immunomodulator therapy within 6 weeks of the study vaccines. Individuals on a tapering dose schedule of oral steroids lasting < 7 days and individuals (e.g., asthmatics) on a short schedule of oral steroids lasting 3 to 4 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment. Topical steroids are not included in this exclusion criterion.

- Anticipated to receive oral or injected antibiotic therapy within the 72 hours prior to the study blood draw. Topical antibiotics or antibiotic drops are not included in this exclusion criterion.

- Suspected or known hypersensitivity to any of the vaccine components.

- Thrombocytopenia or a bleeding disorder contraindicating intramuscular (IM) vaccination.

- Parent or legal guardian unable or unwilling to comply with the stu dy procedures.

- Participation in another interventional clinical trial in the 30 days preceding enrollment, or participation in another clinical trial involving the investigation of a drug, vaccine, medical procedure, or medical device during the subject's trial period.

- Diagnosed with any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine.

- Received any vaccine in the 30-day period prior to receipt of study vaccine, or scheduled to receive any vaccination other than influenza vaccination and hyposensitization therapy in the 30-day period after receipt of any study vaccine. Hyposensitization therapy and influenza vaccination may be received up to 14 days before or 14 days after receiving the study vaccines.

- History of seizures, including febrile seizures, or any other neurologic disorder.

- Personal or family history of Guillain-Barré Syndrome (GBS).

Study Design


Intervention

Biological:
Meningococcal Polysaccharide Tetanus Protein Conjugate
0.5 mL, Intramuscular
Meningococcal Polysaccharide Tetanus Protein Conjugate
0.5 mL, Intramuscular
Meningococcal Polysaccharide Tetanus Protein Conjugate
0.5 mL, Intramuscular
Meningococcal Polysaccharide Tetanus Protein Conjugate
0.5 mL, Intramuscular
Meningococcal Polysaccharide Tetanus Protein Conjugate
0.5 mL, Intramuscular
Dietary Supplement:
Meningococcal polysaccharide group C conjugated
0.5 mL, Intramuscular

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sanofi Pasteur, a Sanofi Company

Country where clinical trial is conducted

Australia, 

References & Publications (1)

McVernon J, Nolan T, Richmond P, Reynolds G, Nissen M, Lambert SB, Marshall H, Papa T, Rehm C. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugat — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary To provide information concerning the safety and immunogenicity after administration of TetraMenT 30 days after each injection
See also
  Status Clinical Trial Phase
Withdrawn NCT03445416 - Increasing Healthcare Engagement Via Routine Vaccination Among Young Black Men Who Have Sex With Men N/A
Completed NCT02526394 - Pertussis and Meningitis C Concomitant Vaccination in Adolescents Phase 4
Completed NCT01442675 - Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine Phase 2
Completed NCT00539032 - Immunology and Safety of Menactra® in Children in Saudi Arabia Phase 3
Terminated NCT00428051 - Colombia Epidemiologic Surveillance Study N/A
Recruiting NCT05496673 - Meningitis: Burden, Causes, Screening and Prevention in Rural Northern Uganda N/A
Completed NCT02003495 - Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine Phase 3
Recruiting NCT00901602 - Lebanese Interhospital Pneumococcal Surveillance Program
Completed NCT00850603 - Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune® Phase 4
Completed NCT02591290 - Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects Phase 4
Completed NCT03112031 - Treatment With Tamoxifen in Cryptococcal Meningitis Phase 2
Completed NCT02881957 - Hypovitaminosis D in Neurocritical Patients Phase 2/Phase 3
Completed NCT06334796 - Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology Early Phase 1
Completed NCT03378258 - Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.
Recruiting NCT05637645 - Different Approaches of Spinal Anesthesia in Patients Undergoing Cesarean Section N/A
Completed NCT02841254 - Diagnostic Performance of Clinical Signs Patients Suspected of Meningitis to Emergencies N/A
Completed NCT02003313 - Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine Phase 3
Recruiting NCT01619462 - Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children Phase 3
Completed NCT01239043 - Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination Phase 2
Completed NCT00495690 - Impact of Daily Zinc Supplementation to Infants Born With Low Birth Weight on Death and Severe Disease Phase 3

External Links